Status:
UNKNOWN
Retrospective Comparison of the Efficacy of Methotrexate and Azathioprine as Background Treatment for Uveitis of Undetermined Origin: Single-centre Retrospective Study From 2005 to 2020
Lead Sponsor:
University Hospital, Brest
Conditions:
Uveitis
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective study at the Brest universitary hospital to evaluate the efficacy of methotrexate (MTX) and azathioprine (AZA) in background treatment of unidentified non anterior uveitis.
Detailed Description
Uveitis is a major cause of ocular damage, responsible for 5 to 10% of blindness in the world. More broadly, up to 35% of patients with uveitis have visual acuity impairment ranging from "significant"...
Eligibility Criteria
Inclusion
- Patient age\>18 years
- Intermediate, posterior or panuveitis diagnosed clinically by an ophthalmologist.
- Patient treated with azathioprine or methotrexate
Exclusion
- Patient under legal protection
- Methotrexate dose \< 10mg or azathioprine \< 50mg
- Systemic or ophthalmological disease (Behçet, sarcoidosis, Retinopathy of Birdshot, etc.)
- Infectious uveitis
- Ophthalmological surgery \< 30 days
- Delayed corticosteroid ocular implant \> 3 months
- Introduction of biotherapy simultaneously or prior to immunosuppressive treatment
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05370690
Start Date
May 1 2022
End Date
November 1 2022
Last Update
May 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Brest
Brest, France, 29609